Literature DB >> 19181784

A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.

Eisaku Iwanaga, Tomoko Nanri, Naofumi Matsuno, Toshiro Kawakita, Hiroaki Mitsuya, Norio Asou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19181784      PMCID： PMC2649368          DOI： 10.3324/haematol.13283

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.

Authors:  F Kuchenbauer; S Schnittger; T Look; G Gilliland; D Tenen; T Haferlach; W Hiddemann; C Buske; C Schoch
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

2.  JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.

Authors:  S Schnittger; U Bacher; W Kern; C Haferlach; T Haferlach
Journal:  Leukemia       Date:  2006-11-09       Impact factor: 11.528

3.  Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.

Authors:  Thomas Illmer; Markus Schaich; Gerhard Ehninger; Christian Thiede
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

4.  JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.

Authors:  C Vicente; I Vázquez; N Marcotegui; A Conchillo; C Carranza; G Rivell; E Bandrés; I Cristobal; I Lahortiga; M J Calasanz; M D Odero
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

5.  JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia.

Authors:  Konstanze Döhner; Juan Du; Andrea Corbacioglu; Claudia Scholl; Richard F Schlenk; Hartmut Döhner
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

6.  A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

Authors:  Shuichi Miyawaki; Hisashi Sakamaki; Shigeki Ohtake; Nobuhiko Emi; Fumiharu Yagasaki; Kinuko Mitani; Shin Matsuda; Yuji Kishimoto; Yasushi Miyazaki; Norio Asou; Takafumi Matsushima; Masatomo Takahashi; Yoshiaki Ogawa; Sumihisa Honda; Ryuzo Ohno
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

7.  Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

Authors:  T Nanri; N Matsuno; T Kawakita; H Suzushima; F Kawano; H Mitsuya; N Asou
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

8.  The JAK2 V617F mutation in de novo acute myelogenous leukemias.

Authors:  J W Lee; Y G Kim; Y H Soung; K J Han; S Y Kim; H S Rhim; W S Min; S W Nam; W S Park; J Y Lee; N J Yoo; S H Lee
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

9.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Authors:  Roberto Cairoli; Alessandro Beghini; Giovanni Grillo; Gianpaolo Nadali; Francesca Elice; Carla Barbara Ripamonti; Patrizia Colapietro; Michele Nichelatti; Laura Pezzetti; Monia Lunghi; Antonio Cuneo; Assunta Viola; Felicetto Ferrara; Mario Lazzarino; Francesco Rodeghiero; Giovanni Pizzolo; Lidia Larizza; Enrica Morra
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

Review 10.  The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications.

Authors:  Norio Asou
Journal:  Crit Rev Oncol Hematol       Date:  2003-02       Impact factor: 6.312
View more
  7 in total

1.  Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.

Authors:  Norio Asou; Eisaku Iwanaga; Tomoko Nanri; Hiroaki Mitsuya
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

3.  Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia.

Authors:  Eisaku Iwanaga; Tomoko Nanri; Hiroaki Mitsuya; Norio Asou
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

4.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

5.  Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory.

Authors:  Wanming Zhao; Rufei Gao; Jiyun Lee; Shu Xing; Wanting T Ho; Xueqi Fu; Shibo Li; Zhizhuang J Zhao
Journal:  J Hematol Oncol       Date:  2011-01-14       Impact factor: 17.388

6.  JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

Authors:  M-C Lo; L F Peterson; M Yan; X Cong; J H Hickman; R C Dekelver; D Niewerth; D-E Zhang
Journal:  Leukemia       Date:  2013-07-01       Impact factor: 11.528

Review 7.  Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Wenlan Chen; Hui Xie; Hongxiang Wang; Li Chen; Yi Sun; Zhichao Chen; Qiubai Li
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.